新型冠状病毒感染对肿瘤治疗的影响

2019年12月新型冠状病毒（severe acute respiratory syndrome coronavirus 2,SARS-CoV-2）在全球蔓延,促使世界卫生组织宣布2019冠状病毒病（COVID-19）流行为国际性突发公共卫生事件。人群普遍易感SARS-CoV-2,而肿瘤患者由于肿瘤生长和抗癌治疗抑制全身免疫系统,成为更易感染并发展为重症SARS-CoV-2症状的脆弱人群。SARS-CoV-2感染后的炎症因子风暴与免疫抑制在SARS-CoV-2感染的肿瘤患者体内产生矛盾,其表现和预后及治疗结果仍未明确。本文基于现有研究文献综述,旨在了解SARS-CoV-2感染对肿瘤患者的生物学及生存预后的影响,以期为疫情期间肿瘤患者的临床治疗提供参考。 

Effect of SARS-CoV-2 infection on tumor therapy

Since December 2019, there has been an outbreak of the novel coronavirus disease (COVID-19), a respiratory disorder caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease has spread worldwide at an alarming rate, leading the World Health Organization to declare COVID-19 a pandemic and public health emergency. The global population is now generally susceptible to SARS-CoV-2; however, patients with cancer are among the populations considered to be highly vulnerable to infection with SARS-CoV-2 and the development of more severe SARS-CoV-2 symptoms. This vulnerability is possibly because of the systemic immunosuppressive state caused by tumor growth and its effects on anticancer treatment. The performance, prognosis, and treatment outcomes of the cytokine storm after SARS-CoV-2 infection and immunosuppression in SARS-CoV-2-infected patients with cancer remain unclear. Based on existing literature, this study aimed to determine the biological effects of SARS-CoV-2 infection on patients with cancer and assess the effect on survival outcomes and prognosis, in order to provide reference for the clinical treatment of tumor patients during the epidemic.